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Abstract
Advanced malignant pleural mesothelioma (MPM) has an extremely poor prognosis with limited chemotherapy options, there-
fore the identification of new therapeutic targets would aid in disease management. Arachidonic acid is metabolised by cyclo-
oxygenase and lipoxygenase enzymes. The lipoxygenase isoenzymes 5-LOX and 12-LOX have been implicated in carcinogen-
esis. We aimed to examine 5-LOX and 12-LOX protein expression in a large retrospective series of mesothelioma samples.
Further to this, the in vitro cytotoxic effects of lipoxygenase pathway inhibitors were investigated in mesothelioma cells. Archival
samples from 83 patients with MPM were examined by immunohistochemistry for expression of the 5-LOX and 12-LOX
proteins. The MTS assay was used to assess cell viability following 72 h treatment with the lipoxygenase pathway inhibitors
baicalein, licofelone, MK-886 and zileuton in the MPM cell lines NCI-H2052, NCI-H2452 and MSTO-211H. Positive 12-LOX
protein expression was recorded in 69/83 (83%) and positive 5-LOX expression was observed in 56/77 (73%) of MPM tissue
samples. Co-expression of 5-LOX with 12-LOX was seen in 46/78 (58%) of MPM samples. Positive expression of 5-LOX, 12-
LOX and COX-2 proteins was identified in the NCI-H2052, NCI-H2452 and MSTO-211HMPM cell lines. Baicalein (12-LOX
and 15-LOX inhibitor) was effective in 3/3 MPM cell lines at low concentrations with an IC50 range of 9.6 μM to 20.7 μM.We
have demonstrated that the 5-LOX and 12-LOX proteins are expressed in a significant proportion of MPM samples (73% and
83% respectively) and may represent novel therapeutic targets in this disease. We have demonstrated that the inhibition of the
LOX pathway using baicalein may be effective as a novel treatment for MPM, however further human pharmacokinetic studies
are required in order to establish whether the concentration used in vitro is clinically achievable.









MPM Malignant pleural mesothelioma
NSCLC Non small cell lung cancer
PGE2 Prostaglandin E2
Introduction
Malignant pleural mesothelioma (MPM) is a rare, aggressive
tumour. Despite recent advances in chemotherapy, it is
Electronic supplementary material The online version of this article
(https://doi.org/10.1007/s12253-019-00652-x) contains supplementary
material, which is available to authorized users.
* Lily Oguh-Olayinka
L.Cawkwell@hull.ac.uk
1 Research Laboratories, Hull York Medical School, Daisy Building,
Castle Hill Hospital, Hull HU16 5JQ, UK
2 Queens Centre for Oncology and Haematology, Hull and East
Yorkshire NHS Trust, Hull, UK
3 Histopathology Department, Hull and East Yorkshire NHS Trust,
Hull, UK
4 Department of Pharmaceutical Chemistry, Eberhard Karls
University, Tübingen, Germany
5 Department of Biomedical Science, University of Hull, Hull, UK
Pathology & Oncology Research
https://doi.org/10.1007/s12253-019-00652-x
associated with a universally poor prognosis. In 80% of cases,
MPM can be attributed to asbestos fibre exposure with a me-
dian latency of at least 32 years [1, 2]. Histologically MPM
can be classified into epithelial, biphasic and sarcomatoid sub-
types. The epithelial subtype is associatedwith longer survival
when compared with sarcomatoid [3, 4]. With the administra-
tion of cisplatin/pemetrexed the median survival of MPM is
still only 12 months and currently there is no widely approved
second line regimen after failure of first line treatment [5–8].
Arachidonic acid is metabolised by lipoxygenase (LOX)
enzymes to form leukotrienes (LTs) and by cyclooxygenase
(COX) enzymes to form prostanoids, including prostaglandin
E2 (PGE2) which has been implicated in inflammation and
carcinogenesis [9–13]. COX exists in two forms, COX-1
and COX-2. COX-2 is overexpressed in a wide variety of
tumours and this feature has been correlated with the malig-
nant properties of cancers. Inhibition of COX-2 has been re-
ported to reverse malignant behaviour such as antiapoptosis,
angiogenesis and invasion [14, 15] and epidemiological evi-
dence suggests that regular use of COX-2 inhibitors may re-
duce the risk of several cancers [16]. We have previously
shown using immunohistochemistry (IHC) that COX-2 is
overexpressed in MPM and that the specific COX-2 inhibitor
DuP-697 can potentiate the in vitro cytotoxic effects of
pemetrexed in MPM cell lines [4, 17]. Functional interactions
between COX-2 and LOX enzymes have been identified [18]
and, of the three known LOX isoenzymes (5-LOX, 12-LOX
and 15-LOX), 5-LOX and 12-LOX have also been implicated
in carcinogenesis [13, 19]. The 5-LOX enzyme interacts with
5-LOX activating protein (FLAP) and converts arachidonic
acid into LTA4. LTA4 can be converted into 5-
hydroxyeicosatetraenoic acid (HETE) or can be hydrolysed
into LTB4 or LTC4 [12, 20]. LTB4 has been shown to cause
cell proliferation and survival via its action on the ERK path-
way in colon cancer cell lines and via the PI3K-AKT and
MAPK pathways in pancreatic cancer cell lines [21, 22].
Arachidonic acid is converted into 12-HETE by its interaction
with 12-LOX [20]. The 12-HETE enzyme interacts with the
NFkB pathway, resulting in an antiapoptotic effect, in prostate
cancer cells [23] and may interact with various growth factors
resulting in angiogenesis, invasion and metastasis [24]. The
expression of 5-LOX and 12-LOX has been associated with
carcinogenesis in various solid tumours. Hong and colleagues
reported the first evidence of the potential role for 5-LOX in
cancer through the demonstration of expression of 5-LOX and
FLAP transcripts in different epithelial cancer cell lines [25].
Increased expression of 5-LOX and LTB4 transcripts was later
demonstrated in human pancreatic cancer cells, when com-
pared with cultivated normal pancreatic ductal cells [26] and
a 6-fold upregulation of 5-LOX transcripts was demonstrated
in prostate cancer tissue, when compared with a matched be-
nign tissue sample [27] The overexpression of 5-LOX protein
was demonstrated in 22 matched samples of benign and
malignant tissue obtained from patients with prostate cancer,
when assessed by immunoblotting and IHC [27]. This immu-
noblotting analysis demonstrated overexpression of 5-LOX
protein in 73% of samples with a 2.6 fold greater expression
in the malignant tissue and the immunohistochemical analysis
confirmed the up-regulation of 5-LOX protein in malignant
tissue [27]. Further studies on the overexpression of LOX
enzymes have since been documented in other epithelial can-
cers, including bladder [28], breast [29], colon [30], melano-
ma [31], oesophagus [32, 33], and oral [34]. The role of LOX
enzymes in MPM has not been widely studied. 5-LOX tran-
scripts were demonstrated to be upregulated in MPM cell
lines, when compared with normal mesothelial cells, whilst
the expression of 12-LOX transcripts was detected in both
normal and malignant cells [35]. We therefore aimed to inves-
tigate the importance of 5-LOX and 12-LOX protein expres-
sion in MPM and benign pleura tissue samples and to study
the effects of in vitro inhibition of the arachidonic acid path-
way in MPM cell lines.
Materials and Methods
Archival Tissue Samples
Research Ethics Committee approval was granted for the
study (ref 11/00/212). Archival MPM tissue samples were
obtained from 83 patients diagnosed between 1992 and
2000 at Hull Royal Infirmary, UK. The majority of patients
were male (76/83; 92%). The original diagnostic histology
slides were reviewed by a histopathologist specialising in
MPM (AC) and clinicopathological details for all samples
were available. There were 44/83 (53%) epithelial, 25/83
(30%) biphasic and 14/83 (17%) sarcomatoid histological
subtypes. In order to investigate benign pleural tissue, 8 archi-
val samples were obtained which were derived from male
patients who had undergone thoracoscopic intervention to pre-
vent recurrence of spontaneous pneumothorax. These 8 sam-
ples were classified histologically by a histopathologist (AC)
into non-reactive (n = 2), mildly reactive (n = 2) and very re-
active (n = 4) based on the reactivity of the mesothelial cells.
Immunohistochemistry
The 83 archival MPM tissue samples and 8 benign pleural
tissue samples were analysed by IHC as previously described
[36] with minor modifications. In brief, endogenous peroxi-
dase enzymes were blocked and antigens were heat-retrieved
by boiling under pressure for 3 min at 15 psi in 1:100 Antigen
Unmasking Solution (H-3300, Vector Laboratories Inc.) with-
in a stainless steel pressure cooker. Non-specific staining was
blocked using normal horse serum (#PK-7800, Vector
Laboratories Inc.) and endogenous biotin and avidin binding
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sites were also blocked (#SP-2001, Vector Laboratories Inc.).
Incubations with anti 5-LOX (#ab169755, Abcam) or anti 12-
LOX (#ab23678, Abcam) antibodies were performed using a
dilution of 1:100 for 2 h. Negative (antibody-omitted) control
and positive control slides, which consisted of archival colo-
rectal cancer tissue, were included in each batch. Antibody
localisation was detected and visualised using a streptavidin/
peroxidase method (#PK-7800, Vector Laboratories Inc.) with
DAB as chromogen. Slides were counterstained with
haematoxylin and independently reviewed by 3 of the co-au-
thors, including a histopathologist specialising in MPM (AC).
Discordant scores were reviewed in open discussion. For
MPM samples, Bpositive^ protein expression was recorded if
there was moderately strong staining in more than 25% of the
malignant cells and Bnegative^ protein expression was record-
ed if no, or only weak, staining was seen or if staining was
seen in less than 25% of the malignant cells.
Statistical Analysis
Statistical analysis was performed using SPSS software ver-
sion 19.0 (SPSS, Chicago, USA). Univariate analysis was
carried out for 5-LOX and 12-LOX expression using Kaplan
Meier survival curves with log rank analysis. Multivariate
analysis was calculated using Cox regression analysis to take
into account the histological subtypes which are known to be
an independent prognostic variable in MPM [4].
Cell Lines
The MPM cell lines NCI-H2452, NCI-H2052 and MSTO-
211H were obtained from the American Type Culture
Collection (ATCC). In addition, the non-small cell lung cancer
(NSCLC) cell line A549 was obtained from the European
Collection of Cell Cultures (ECACC). Cells were grown in
RPMI 1640 medium supplemented with 2 mM L-glutamine,
10% (v/v) foetal bovine serum, 100 U/ml penicillin and
100 μg streptomycin in a humidified incubator with 5%
CO2 at 37 °C. Cell lines were passaged at 70–80% confluence
and regularly checked for mycoplasma contamination.
Cell Lysis and Immunoblotting
Cells were grown to 70–80% confluence in then lysed in
Laemmli buffer (65 mM Tris-HCl pH 6.8, 10% glycerol, 2%
SDS, 0.001% bromophenol blue) with the addition of 5% β-
mercaptoethanol and 1% protease inhibitor mix (#80–6501-
23, Amersham Biosciences). Protein lysates were quantified
using the RCDC protein assay (# 500–0122, Biorad) and
50 μg of protein was analysed per lane on a 12% acrylamide
gel (#25222, Pierce) under reducing conditions and trans-
ferred to a nitrocellulose membrane using a semi-dry iBlot
system (Life Technologies). Membranes were blocked in 5%
non-fat milk before samples were probed for 2 h with the anti
5-LOX antibody (#ab39347, Abcam) at a final concentration
of 1:250 and the anti 12-LOX antibody (#ab23678, Abcam) at
a final concentration of 1:500. To serve as a loading control,
the anti α-tubulin antibody (#ab7291, Abcam) was applied at
1:3000 for 2 h. Visualisation of protein bands was achieved
using the SuperSignal West Pico Chemiluminescent Substrate
kit (#34078, Pierce).
Cell Cytotoxicity Assay
Commercially available inhibitors were purchased as follows:
zileuton (#3308, Tocris Bioscience), which is a 5-LOX inhib-
itor [37]; MK-886 (#1311, Tocris Bioscience), which is a
FLAP inhibitor [38]; baicalein (#1761, Tocris Bioscience),
which is a 12-LOX and 15-LOX inhibitor [39]; celecoxib
(#3786, Tocris Bioscience), which is a selective COX-2 inhib-
itor [40]. In addition, licofelone (ML3000) was provided as a
gif t by Professor Stefan Laufer (Depar tment of
Pharmaceutical Chemistry, Eberhard Karls University,
Tübingen, Germany). Licofelone is a dual COX/5-LOX in-
hibitor [41]. Stock drug solutions were prepared in DMSO
and stored at -20 °C for further use. Drugs were diluted in
fresh media prior to each experiment. Cells were plated in
96-well plates at 1 × 103 cells/well and grown overnight in
supplemented media as above. After 24 h, cells were treated
in replicates of 6 and cell viability was measured after 72 h
using the CellTiter 96 Aqueous One Solution Cell
Proliferation Assay (#G3581, Promega). Following the 3 h
labeling of metabolically active cells with MTS, results were
measured at 492 nm using an absorbance plate reader
(Multiskan FC Microplate photometer, Thermo Scientific).
Values were normalised to untreated control cells in order to
generate dose response curves. At least 3 independent exper-
iments were carried out for each drug analysis before IC50
values were calculated using GraphPad Prism 5.0 software.
Student’s paired t test was used to assess the differences ob-
served between single agent treatment and combinations
(p < 0.05). To assess drug synergy between celecoxib and
baicalein on cell growth inhibition of the cell lines, a combi-
nation index (CI) was calculated using data obtained from the
MTS assay. Concentration-effect curves were generated as a
plot of the fraction of unaffected cells versus drug concentra-
tion in accordance with the Chou-Talalay method [42] using
the following CI equation: CI = (D1)/(D1a) + (D2)/(D2a) +
(D1 x D2)/(D1a x D2a), where D1 and D2 are the concentra-
tions of baicalein and celecoxib respectively that exhibited a
determined effect when applied simultaneously to the cells
and D1a and D2a are the concentrations of these drugs that
exhibited the same determined effect when used as single
agents. The CI values indicate a synergistic effect when <1,
an additive effect when equal to 1 and an antagonistic effect
when >1 [42].
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Fig. 1 Expression of 12-LOX protein demonstrated by IHC using
primary antibody ab23678 (Abcam). a Negative control (antibody
omitted) (× 100). b Positive control (colorectal cancer with adjacent
normal mucosa, × 100). c, d 12-LOX expression in non-reactive benign
pleural tissue (× 100 and × 400 respectively). e Epithelial subtype of
MPM demonstrating strong positive expression (× 400). f Biphasic
subtype of MPM demonstrating negative expression (× 400)
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Results
Expression of 12-LOX Protein
All 8/8 benign pleural samples exhibited similar nuclear and
cytoplasmic staining patterns, irrespective of their reactive
status (Fig. 1). In the MPM samples the expression of the
12-LOX protein was again predominantly found in the nucle-
us and cytoplasm of the malignant cells, with varying intensity
(Fig. 1). Positive 12-LOX protein expression was recorded in
69/83 (83%) of MPM tissue samples (Table 1). The expres-
sion of 12-LOX was not associated with survival (p = 0.455).
Expression of 5-LOX Protein
The 8 benign pleural samples exhibited differential expression of
the 5-LOX protein based on their reactive status (Fig. 2). Where
staining was observed, 5-LOX protein was localised to the cy-
toplasm and nucleus. Few inflammatory cells were seen in the 2
non-reactive pleural samples and the mesothelial cells exhibited
no expression of 5-LOX protein.Mildly reactive pleural samples
(n = 2) exhibited weak staining for 5-LOX in the mesothelial
cells and very reactive pleural samples (n = 4) exhibited strong
positive staining for 5-LOX in the mesothelial cells (Fig. 2).
Of the 83 MPM tissue samples, 77 samples were success-
fully scored. The immunohistochemical staining revealed nu-
clear and cytoplasmic expression of the 5-LOX protein in
malignant cells with varying intensity (Fig. 2). Positive stain-
ing of lymphocytes and other inflammatory cells served as an
internal positive control. Positive 5-LOX expression was ob-
served in 56/77 (73%) of MPM tissue samples (Table 1).
Overall, the expression of 5-LOX was not associated with
survival (p = 0.640), however when considering only the
sarcomatoid subtype the positive expression of 5-LOX was
significantly associated with improved survival (median sur-
vival 4.2 months versus 1 month in 5-LOX negative cases;
p = 0.028) (online resource 1).
Correlations Between 5-LOX, 12-LOX and COX-2
Expression
Co-expression of 5-LOX with 12-LOX was seen in 46/78
(58%) of the MPM samples but this was neither statistically
significant nor associated with survival. We have previously
published the COX-2 protein expression data for this cohort
[4] (Table 1). A total of 41/77 (53%) of samples demonstrated
co-expression of COX-2 with 5-LOX proteins and this status
was significantly associated with improved survival when
compared with cases which were negative for both proteins
(median survival 8.7 months versus 2.2 months; p = 0.011)
(online resource 1). Co-expression of COX-2 with 12-LOX
was seen in 47/83 (56%) of the samples. In univariate analysis
cases demonstrating a COX-2 positive /12-LOX negative sta-
tus or co-expression of COX-2 with 12-LOX were associated
with longer survival (online resource 1).
Expression 5-LOX and 12-LOX in MPM Cell Lines
The protein expression of 5-LOX and 12-LOX in the MPM
cell lines is shown in Fig. 3 and the relative expression levels
following normalisation, are summarised in Table 2. We have
previously reported the expression of COX-2 in these cell
lines [4]. Positive expression of 5-LOX, 12-LOX and COX-
2 proteins was identified in all of the MPM cell lines and the
NSCLC cell line A549.
Effect of LOX Pathway Inhibitors on Cell Viability
Cell viability was determined in all cell lines following single-
agent treatment for 72 h with increasing concentrations of the
LOX pathway inhibitors baicalein, MK-886, zileuton and
licofelone, in addition to the COX-2 inhibitor celecoxib (Fig.
3, Table 3). Celecoxib (COX-2 inhibitor) demonstrated similar
anti-proliferative effects in all MPM cell lines with an IC50
range of 39.2 μM to 48.1 μM. At low concentrations, zileuton
(5-LOX inhibitor) and licofelone (dual COX/5-LOX) inhibitor
did not demonstrate an effect in any of theMPMcell lines.MK-
886 (FLAP inhibitor) exerted an effect at low concentrations in
2/3 of the MPM cell lines, however baicalein (12-LOX and 15-
LOX inhibitor) was effective in 3/3 MPM cell lines at low
concentrations with an IC50 range of 9.6 μM to 20.7 μM.
Effect of Combined Use of COX-2 and LOX Pathway
Inhibitors on Cell Viability
As a proof of principle, we investigated the effect of combin-
ing celecoxib and baicalein on cell viability using a clinically
achievable concentration of celecoxib (3 μM; Table 3). A
Table 1 Immunohistochemical




Total Epithelial Biphasic Sarcomatoid
12-LOX positive 69/83 (83%) 38/44 (86%) 21/25 (84%) 10/14 (71%)
5-LOX positive 56/77 (73%) 30/42 (71%) 18/22 (81%) 8/13 (62%)
COX-2 positivea 58/93 (62%) 37/48 (77%) 15/27 (56%) 6/18 (33%)
aData for this cohort as previously reported 4
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concentration of 10 μM was selected for baicalein based on
the single-agent IC50 data for the MPM cells (Table 3). Cell
viability was determined following combined treatment for
72 h (Fig. 4).
Discussion
MPM is highly resistant to tyrosine kinase inhibitors and the
preferred treatment remains the combination of a platinum-
Fig. 2 Expression of 5-LOX protein demonstrated by IHC using
primary antibody ab169755 (Abcam). a Negative control (antibody
omitted) (× 100). b Positive control (colorectal cancer with adjacent
normal mucosa, × 100). c Benign pleural tissue with non-reactive
mesothelial cells, which can be seen as an organised strip of mesothelial
cells on the surface (red arrows), exhibiting no expression of 5-LOX
protein. Inflammatory cells (black arrow) can be seen in the connective
tissue (× 400). d Benign pleural tissue with reactive mesothelial cells and
inflammatory cells demonstrating positive expression for 5-LOX (× 400).
e Epithelial subtype ofMPMdemonstrating positive expression (× 400). f
Epithelial subtype of MPM demonstrating negative expression (× 400)
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based compound and a folate antimetabolite [5, 7, 8]. There
are currently no approved second-line treatments for patients
who do not respond to the chemotherapy regimen indicating
an urgent need for the development of more effective therapies
and a better understanding of this malignancy. Previous stud-
ies have demonstrated the potential role of COX-2 as a thera-
peutic target in MPM [4, 43–45] and the selective COX-2
inhibitor celecoxib has been included, in combination with
other drugs, in clinical trials for patients with MPM [46]. In
the current study we have demonstrated that the 5-LOX and
12-LOX proteins are expressed in a significant proportion of
MPM samples (73% and 83% respectively) andmay represent
novel therapeutic targets in this disease. The co-expression of
COX-2 with 5-LOXwas associated with improved survival in
this cohort and, in the sarcomatoid subtype only, the
expression of 5-LOXwas associated with improved prognosis
however these preliminary findings require further confirma-
tion using a larger number of cases. The benign samples used
in this study were from patients with an underlying condition
which may lead to the presence of reactive mesothelial cells
due to inflammation. 12-LOX expression was seen in non-
reactive and reactive benign pleural tissue samples whilst 5-
LOX expression was evident only in cases with reactive me-
sothelial cells. To our knowledge, this is the first study to
investigate 5-LOX and 12-LOX protein expression in MPM
tissue samples.
A panel of MPM cell lines, which exhibited expression of
the COX-2, 5-LOX and 12-LOX targets, demonstrated no
response to treatment for 72 h with the 5-LOX inhibitor
zileuton at the clinically relevant concentration range. In each
cell line, the IC50 for celecoxib was reached at a concentration
which was outside the clinically relevant range. The maxi-
mum tolerated dose for baicalein, MK-886 and licofelone in
humans is not available and therefore to further examine the
in vitro effects of simultaneous inhibition of the COX-2 and
LOX pathways we examined baicalein in combination with
celecoxib, which was used at the clinically relevant concen-
tration. Baicalein, which is known to inhibit 12-LOX as well
as 15-LOX [39], had demonstrated an effect in all 3 MPM cell
lines at relatively low concentrations as single agent when
compared to the other LOX pathway inhibitors. Baicalein
has been reported to reduce cell proliferation in vitro in other
cancer cell lines at concentrations of 5–80 μM [47–50] and
Fig. 3 Effect of COX-2, LOX and FLAP inhibitors on the viability of
MPM cells. a Immunoblotting analysis of the NSCLC cell line A549 and
the MPM cell lines NCI-H2452, NCI-H2052 and MSTO-211H. b-f Cell
proliferation (MTS) assays to investigate the single-agent effect in MPM
and A549 cells of a COX-2 inhibitor (celecoxib), a 12-LOX/15-LOX
inhibitor (baicalein), a FLAP inhibitor (MK-886), a 5-LOX inhibitor
(zileuton) and a dual COX/LOX-5 inhibitor (licofelone) respectively.
Following treatment for 72 h, cell viability was determined using the
MTS reagent and expressed as a ratio of cell viability in comparison to
the relevant control (cells treated with <0.1% dimethyl sulfoxide). Each
data point is the mean of 18 replicates and error bars represent the stan-
dard error of the mean. The IC50 values generated are shown in Table 2
Table 2 Immunoblotting analysis of the COX-2, 5-LOX and 12-LOX
proteins. The relative expression, following normalisation of the bands
shown in Fig. 3(a), is summarised for 3 MPM cell lines (NCI-H2452,
NCI-H2052, MSTO-211H) and the NSCLC cell line A549
Cell line COX-2a 5-LOX 12-LOX
A549 ++ ++ ++
NCI-H2452 +++ ++ ++
NCI-H2052 ++ +++ ++
MSTO-211H ++ ++ +
aData previously reported for this cell line panel 4
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may induce cancer cell death via inhibition of CDC2 kinase
and survivin [48]. There has only been one previous report of
the baicalein treatment of MPM cells and no effect was seen
when using a single fixed concentration of 2 μM [35]. The
Fig. 4 Effect of combining celecoxib with baicalein on the viability of
MPM cells. Cell proliferation (MTS) assays were performed to
investigate the combined effects of 3 μM celecoxib (COX-2 inhibitor)
with 10μMbaicalein (12-LOX and 15-LOX inhibitor) in the NSCLC cell
line A549 and the MPM cell lines NCI-H2452, NCI-H2052 and MSTO-
211H. Following treatment for 72 h, cell viability was determined using
the MTS reagent. The data represents the mean and standard deviation of
six replicates from at least three independent experiments and the
statistical significance of the combination versus celecoxib-alone is
shown (ns – not significant; * p = 0.01 to 0.05; *** p = 0.0001 to
0.001). The Chou-Talalay combination index (3.38 in A549; 1.72 in
NCI-H2452; 1.36 in NCI-H2052; 0.73 in MSTO-211H) indicates a
synergistic effect of celecoxib and baicalein in the MSTO-211H cells at
the selected doses
Table 3 The effect of arachidonic acid pathway inhibitors onMPM cells.
As shown in Table 2, all cell lines demonstrated expression of 5-LOX, 12-
LOX and COX-2 proteins. The IC50 values, calculated from the data
shown in Fig. 3, are shown for the MPM cell lines (NCI-H2452, NCI-
H2052, MSTO-211H) and the NSCLC cell line A549. For reference, the
published human Cmax range for each inhibitor was converted into the
equivalent molar concentrations. Baicalein, MK-886 and licofelone do
not currently have a published recommended daily dose and therefore the
clinically achievable Cmax may be higher than shown




3.0–6.2 μM at the
recommended daily dose






14.1–22.8 μM at the
recommended daily dose
of 2400 mg per day 58
Dual COX/5-LOX
2.9–6.2 μM 59
A549 47.9 μM 28.8 μM 29.7 μM 307.5 μM 58.6 μM
NCI-H2452 39.2 μM 10.7 μM 39.0 μΜ 342.7 μΜ 80.7 μΜ
ΝCΙ-Η2052 48.1 μΜ 20.7 μΜ 84.0 μΜ 579.2 μΜ 140.0 μΜ
ΜSΤΟ-211Η 42.2 μΜ 9.6 μΜ 30.5 μΜ 137.3 μΜ 99.7 μΜ
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in vitro combination results indicated that celecoxib/baicalein
treatment may be more effective than celecoxib alone in these
cell lines, however 10 μM baicalein alone appears to be main-
ly responsible for this effect with drug synergy demonstrated
in only 1 cell line.
In summary, this study has shown that 5-LOX and 12-LOX
proteins are expressed at high frequency in mesothelioma
samples and may represent therapeutic targets. The role of
15-LOX inMPM requires further study. We acknowledge that
inhibitors used within this study have been previously report-
ed to inhibit tumour cells independent of lipoxygenase inhibi-
tion, hence further studies on the effect of the inhibitors on
PGE2 and LTB4 levels in conjunction with cell death in me-
sothelioma cells requires further evaluation [51–53]. 12-LOX
has also been reported to be predominantly expressed in the
cytoplasm however nuclear localization of 5-LOX and 12-
LOX have been reported previously by [54, 55].
As a proof of principle, we have demonstrated that the
inhibition of mesothelioma cells using baicalein may be effec-
tive as a novel treatment for MPM, however further human
pharmacokinetic studies are required in order to establish
whether the concentration used in vitro is clinically achievable
since the single pharmacokinetic study [56] in humans did not
establish a maximum tolerated dose.
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